Clinical Report: Oral HRS-7535 Lowered A1c in Trial
Overview
Expand on the safety profile to include specific adverse events or tolerability.
Background
Type 2 diabetes management often requires effective glycemic control to prevent complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a key treatment option, but adherence can be challenging due to administration requirements. HRS-7535, a nonpeptide oral GLP-1 RA, offers a promising alternative that does not necessitate fasting, potentially improving patient compliance.
Data Highlights
Dose (mg)
Mean A1c Reduction (%)
Placebo-Adjusted Reduction (%)
% Achieving A1c < 7.0%
15
1.19
0.94
49
30
1.59
1.34
63
60
1.82
1.57
63
90
1.64
1.39
60
Placebo
0.25
-
15
Key Findings
HRS-7535 reduced hemoglobin A1c by up to 1.82 percentage points compared to placebo.
49% to 63% of patients on HRS-7535 achieved A1c levels below 7.0% versus 15% on placebo.
Rescue antihyperglycemic therapy was required in only 3% to 8% of patients receiving HRS-7535, compared to 31% in the placebo group.
Weight reduction was modest, with a maximum of 2.63% in the 90 mg group compared to placebo.
Changes in fasting plasma glucose and postprandial glucose were significantly greater with HRS-7535 than with placebo.
The 60 mg dose provided similar efficacy to the 90 mg dose, suggesting potential for dose optimization.
Clinical Implications
The findings suggest that HRS-7535 may be an effective oral treatment option for patients with type 2 diabetes inadequately controlled on metformin. Its non-fasting requirement could enhance adherence, making it a valuable addition to diabetes management strategies.
Conclusion
HRS-7535 demonstrates significant efficacy in lowering A1c levels in type 2 diabetes patients, warranting further investigation in larger trials to confirm its safety and optimal dosing.
